Health Meaning

A veterinary drug that kills the worms in cattle can also fight against river blindness, a debilitating infection parasite that affects 37 million people across the world, researchers say. But experts warn against the temptation of the compound in humans yet.

blind people contract rivers, also known as onchocerciasis, when bitten by black flies that carry a nematode known as volvulus Onchocerca . Worm larvae mature and mate, producing up to 1000 "microfillariae" offspring per day, which migrate to the surface of the skin and eyes. When microfillariae die, they cause itchy lesions that can lead to blindness. The disease often forces farmers to abandon the many lush river valleys with black flies infected for less fertile areas.

Doctors currently treat river blindness Ivermectin, a drug that kills the microfillariae and reduces the fertility of adult worms. Ivermectin has reduced cases of blindness and injuries in countries such as Senegal and Mali. But ivermectin does not target to nearly mature that cause new infections through the bite of a black fly. Instead, the drug control symptoms until the worms eventually die out. Scientists are still searching a compound that could block infection altogether, for example by killing the teenagers to arrival.

Researchers led by Kim Janda, a chemist at the Scripps Research Institute in San Diego, California, decided to focus on an enzyme called chitinase, which breaks down and rebuilds O. volvulus outer housing larvae during the final molt before adulthood. They screened 1,500 drugs, looking for one that blocked the enzyme. The best candidate turned out to be a veterinary drug known as closantel, which kills liver parasites in cattle. When Janda's team cultivated O almost mature. volvulus larvae in solutions that contained various amounts of the drug for 6 days, only 1.4% of closantel-dosed larvae had moulted against 60% in the control group, reports Team online this week in Proceedings of the national Academy of sciences .

If closantel has the same effect in humans, it could prevent infections begin, said Roger Prichard, parasitology at McGill University in Montreal, Canada. And because it works in a completely different way of ivermectin, he said, all strains of O. volvulus , which show resistance to ivermectin in the future could be treated with closantel.

Janda said he is optimistic about working with closantel as it has already proved safe in farm animals. "This moves the drug discovery process along more quickly."

But Prichard warns that the highway can not be so fast. Closantel is not approved for use in all animals in all countries, including the United States, he said. And it binds to a protein present in the blood, which might lead to side effects in humans. In addition, the team would have to prove that Janda Closantel lasts long enough to provide protection from intermittent doses; one of the reasons why ivermectin works so well is that it should be taken once or twice a year. "It is far from showing inhibition of the enzyme to actually have a drug," said Prichard. "There are significant barriers that must be overcome."

SAN DIEGO -Is babies born through IVF different from those born naturally? And new fertility treatment creating a larger population of infertile? "The answer is maybe yes," said Andre Van Steirteghem of the Brussels University Hospital Center for Reproductive Medicine. In this short podcast Science Robert Frederick listening that Van Steirteghem and other experts have said about the future of assisted reproduction here at the annual meeting of the American Association for the advancement of science (which publishes science NOW).

Frustrated by the cost and slow death pace of drug development, a group of researchers today launched a new unique strategy for clinical trials execution. Their goals are bold. They want to bring many products being tested in a single framework, validation of new biomarkers, data from the public, maintain uniform standards across a wide range of drug candidates, and quickly eliminate the losers. Predicted to cost $ 26 million over 5 years, the project will begin testing new therapies for breast cancer. The leaders say they hope that clinicians working on other diseases copy their experience and melanoma may be next. The experience is launched just about 60% funded, according to its developer, the independent Foundation for the National Institutes of Health.

The project is called I-SPY 2, which just means "the series of studies Survey to predict therapeutic response with your molecular imaging and analysis 2." (It follows a trial driver called I-SPY 1.) the first patients will be enrolled next week, said Laura Esserman, a surgeon at the University of California, San Francisco, who briefed reporters at the National Press Club in Washington, DC She is clinical head the trial. She said five therapeutic agents were selected for initial testing.

Anna Barker, deputy director of the National cancer Institute, said a systemic reform of the trial system is " long overdue. "

One of the promised benefits of the project is a coherent set of knowledge, said Janet Woodcock, director of the Center for evaluation and research on drugs at the US Food and Drug Administration. She called an "experience with a high probability of success." Senator Arlen Specter of Pennsylvania (D) appeared at the briefing to give I-SPY 2 his blessing and remind people that he pushed to increase the annual budget of the national Institutes of health from $ 30 billion to $ 40 billion.

the main objective of I-SPY 2, according to Esserman and others, is to reduce the time it takes for a green or red light for a new drug against the potential breast cancer 10 years to 1 year. other objectives are to identify drugs that work best for cancer patients, using new biomarkers to describe more precisely than before the game between the subtypes and disease treatments. the new strategy provides for the administration of drugs before surgery, usually doctors make the first imaging and surgery precisely the response of tumors before to move to a prolonged medication.

The approach also requires a new set of statistical methods to enable to obtain credible results small test groups. The plan is to predict early drugs that are likely to succeed and which are not, and quickly promote the winners to greater (phase III) trials, which would most likely be run by private companies, without sharing data. Biostatistician Don Berry MDAnderson Cancer Center in Houston, Texas, oversees the data analysis I-SPY 2. The concept, he said, is to continually add new drugs to several weapons in the process, promote few, and remove the rest. Berry concluded: "We hope this trial will last forever"

US farmers have benefited from the introduction of genetically modified crops, according to a new report ^* published today by the National research Council of the National Academies. Farmers who switched from conventional crops have seen higher profits and a reduced environmental impact, the committee concluded. However, many benefits such as improving water quality, need to be better quantified, and some biotech crops are threatened by the development of weeds resistant to herbicides.

Over 80% of corn, soybean, and cotton acreage in the US is planted with modified crops to resist pests and improve weed control. During the last decade, groups of experts convened by the National Research Council examined the potential risks to human health and the environment, such as gene flow between agencies. But they had not taken a broad look at what the impact was on farms that grow biotech crops. For example, NRC commissioned a group of 10 experts combing the scientific literature.

"The evidence is quite strong is that these technologies have both economic and environmental benefits," says David Ervin of Portland State University economist in Oregon, who chaired the panel. But many effects need to be better studied. The committee recommended, for example, the US Geological Survey to study the impact of reduced tillage has had on water quality.

Charles Benbrook, chief scientist of the OrganicCenter in Enterprise, Oregon, is unsure of the persistence of the economic benefits. Benbrook, who was not on the NRC panel, said that strong price increases biotech seeds, which began in 07, could erode economic gains for farmers.

The group also highlighted several risks. One of the most important is that the resistance of insects or weeds will make genetically modified crops inefficient farmers and strength to return to more toxic chemicals or plowing causing soil erosion. Economist Dermot Hayes Ames says State University of Iowa, he is optimistic that new types of crops and biotechnology management will solve the problem of resistance, but Benbrook is less optimistic. "It's a crisis now," he said.

A news story about the report published in this week's issue of Science .

^* The impact of GM crops on agricultural sustainability in the US . Washington The National Academies Press, 2010.

Sufferers of Gilles de la Tourette syndrome are plagued by unwanted movement and verbal tics that range from extra winks and Grimaces involuntary grunts or even curse. Although the disease tends to run in families, little is known about its genetic basis. The researchers found a mutated gene that seems to cause the disorder in a family with nine extremely rare sufferers. While this mutation is the cause of most cases of Tourette's syndrome, it can push researchers to study treatment and potential mechanism they otherwise would not have considered.

Since the French neurologist Georges Gilles de la Tourette first described its namesake state 125 years ago, scientists have puzzled over the cause. Many recent attention has focused on a brain region called the basal ganglia, which is involved in repetitive behaviors and the neurotransmitter dopamine. In 05, a team led by child psychiatrist and geneticist Matthew State of the School of Medicine at Yale University, reported one of the first genetic clues to disease, a mutation in a gene called SLITRK1 seems to be responsible for a rare handful of cases. But the function of SLITRK1 and its contribution to Tourette syndrome is still largely a mystery.

In the new study, the State and his colleagues examined a family in which the father and eight children (six son and two daughters) have the syndrome. Many genetic detective work led them to a mutation in a gene called HDC , which encodes L-histidine decarboxylase, an enzyme involved in the production of histamine, a signaling molecule with a wide variety roles in the body. The same mutation was present in all members of the family who had Tourette's, but was absent in the thousands of DNA samples from control subjects, which included non-related people of similar ethnic backgrounds, as well as a group of 720 Tourette patients, the researchers report today in the New England Journal of Medicine . The mutated version of HDC Genes likely results in a truncated version of the enzyme, which would result in reduced levels of histamine, State said.

histamine may be best known for her role in triggering sneezing and itchy eyes during allergy season, but it also functions as a neurotransmitter in the brain. Exactly how histamine abnormalities contribute to the symptoms of Tourette's syndrome is unclear, but the State notes that knocking out the equivalent of HDC gene makes mice more prone to bobbing head, spinning, and other repetitive behaviors. In addition, he said, there is evidence that some histamine receptors cluster in the basal ganglia and the signaling of histamine can act as a brake on the signaling of dopamine.

"They make a very convincing argument that this mutation in this family is responsible for Tourette's," says Jon McClellan, a psychiatrist at the University of Washington, Seattle. "If histamine is actually an active player in Gilles de la Tourette syndrome, it would really open a new way of treatment" involving drugs that stimulate histamine, says Jeremiah Scharf, a behavioral neurologist and the Neurogeneticist Harvard Medical School in Boston. But he warned that much more work is needed to determine if the results of this family can be leveraged to help thousands of other people with the disorder.

23andMe has informed customers it wrongly mixed samples of less than 96 people, leaving at least one parent would worry that his daughter had been at birth with another baby. The company has not yet commented publicly error, publishing information only to its customers, the reprocessing of samples in question and considering ways to prevent a repeat.

Criticism of Avandia diabetes therapy reached its climax. The drug has been in the spotlight since 07, when it was linked to heart attacks. Yesterday, two new results analysis studies for hundreds of thousands of people have reaffirmed that the drug can be dangerous for the heart and hang the degree of risk close to the conclusion of 07. The company that makes Avandia, GlaxoSmithKline, fired back with a denial that Avandia is dangerous. But the pressure to get the market is running high, and two advisory groups to the US Food and Drug Administration (FDA) meet in a few weeks to discuss what to do.

The new studies were conducted by researchers who have long expressed concerns about Avandia, also known by its generic name rosiglitazone. The first was published online by The Journal of the American Medical Association . There, David Graham, who works in drug safety at the FDA, and colleagues turned to a database of 227.571 people on Medicare, meaning they were older than 65. each of them had been treated with either Avandia or Actos (pioglitazone), a similar drug.

Data on medication use were available through the prescription drug Medicare, which took effect in January. 06 The group of Graham found that people taking Avandia had about a 18% higher risk of heart attack, stroke, heart failure or death compared to those on Actos, which other studies have shown is just as effective.

The second study was conducted by cardiologist Steven Nissen at the Cleveland Clinic in Ohio; Nissen who was there 3 years, triggered the storm with Avandia meta-analysis of 42 trials of Avandia that he said suggested an increased risk of heart attack. In his latest article, published with his colleague Kathy Wolski, published online yesterday in Archives of Internal Medicine , Nissen has updated its previous meta-analysis by analyzing 56 trials and found an additional heart attack for every 52 patients on the drug.

Although both studies have limitations, an accompanying editorial Graham reviewed the convincing conclusions: "Accumulation concerns about rosiglitazone advance difficultto a convincing argument regarding the reason which, exactly, a patient might want to receive the drug. "FDA advisers meet July 13 to give their own judgment whether the drug is safe enough to be used.

A cancer genomics researcher at Duke University was put on leave after administrators learned that falsely claimed he was a Rhodes scholar. The school took the action after Letter cancer in Washington, DC, newsletter, investigated allegations of Anil Potti of being a Rhodes Scholar to several grant applications. The online newsletter reported on Thursday that he learned of the foundation that Rhodes Potti never received the prestigious award, which is given for the study at the University of Oxford in the UK.

Potti explained in an e-mail sent to the newsletter was a candidate for the award, Letter cancer reports. The newsletter was also able to confirm other details in various Potti biographies, including two awards, he said, to have received research organizations on cancer. On Friday, officials told the Duke The News & Observer they put on administrative leave Potti while investigating the allegations.

The American Cancer Society has suspended payments on a research grant to Potti $ 729,000.

Potti is a co-investigator on the research at Duke led by Joseph Nevins on the use of gene expression networks to predict the response of a cancer patient to chemotherapy. Two external statisticians found serious errors in key publications by the Duke group, according to Letter cancer .

The decision of the court yesterday temporarily blocking federal funding for work with human embryonic stem cells (hESCs) left researchers working with cells in limbo government lawyers decide how to react.

Judge Royce Lamberth of the US District Court for the District of Columbia issued a temporary injunction blocking the federal government to implement national current Institutes of Health (NIH) guidelines governing research with hESCs. In his 15-page ruling, Lamberth said that "ESC research necessarily depends upon the destruction of a human embryo." And because Congress each year since 1996 adopted the so-called Dickey-Wicker Amendment, which prevents Government funding "research in which a human embryo or embryos are destroyed," the government can not finance the work with cells.

the decision comes as part of a lawsuit filed a year ago by Christian groups opposed to embryo research. the US district court dismissed the complaint because it found the applicants, including some embryos listed with names, had no legal status . But in June, the Court of the United States of Washington of appeal reinstated the suit. the court ruled that two doctors on the suit, the stem cell scientists James Sherley and Theresa Deisher, do have standing because the lines NIH stem cell guidelines aggrieved by decreasing their chance of receiving funding for work on adult stem cells.

Although the prosecution was led on the rules of the Obama administration to increase funding for hESC research, Lamberth's opinion strongly suggests that funding under the Bush administration was also illegal under the Dickey Amendment.

It is unclear this morning if researchers who had received money from the grant to study hESC-a total of $ 137 million in 2010, could continue their projects. NIH referred journalists to the Ministry of Justice; a spokesman for the Department of Justice said that the department review the decision and had no further comment.

Mazzaschi Anthony, Director of Scientific Affairs of the Association of American Medical Colleges in Washington, DC, sees two options for the Obama administration to avoid the judgment of the current research. Federal lawyers could ask the appellate court to stay the injunction after a trial is held. Or they could issue a restrictive interpretation of the decision which allows continuous research to proceed and see if it is. "We need to take a deep breath and see what the plans of justice are," said Mazzaschi.

Harvard University said its researchers as NIH informed them otherwise, they could continue work on previous grants. But some scientists were taking no chances. George Daley, a researcher on stem cells at the Harvard stem cell Institute, said he had asked his lab members to keep separate any work with the hESC materials purchased with NIH money. "I read the decision, and I would be surprised if someone else can find a way to interpret this as nothing less than a general ban on the use of federal funds for research on human ES cells, "he said.

If the injunction holds the only way for federal funding of hESC research could continue is if Congress passes a law replacing the Dickey Amendment. Representative Diana DeGette (D-CO), co-sponsor of a bill to codify Obama stem cell policy, issued a statement calling the decision "deeply disappointing" and saying that "we have to pass sensible legislation seeking embryonic stem cells. " As an alternative to a stand-alone bill, Congress could add an amendment to a current bill ending the Dickey-Wicker rule.

But Mazzaschi said he is certain that legislators will want to take the legislation on stem cells during the "madness" of a year midterm elections when many Democrats and Republican moderates are vulnerable.

Science Insider will relay updates on the consequences of the injunction.

For more information on the prohibition of stem cells, see our full coverage.

Does the human embryonic stem cell (hESC) research violating the law? And is it logical to stop federal funding of work while the courts weigh this question?

Yesterday, the Chief Justice Royce Lamberth of the US District Court in Washington ruled that the prohibition of funding, it imposed two weeks ago stick for now. The Department of Justice is expected to appeal the decision, which makes it even more complicated case. Meanwhile, scientists of the country, particularly the National Institutes of Health (NIH), where all the work of hESCs is stopped, are exasperated and deeply disturbed by the case.

Although moral opposition to hESC research is certainly helping drive Sherley v. Sebelius , the case also includes complex legal issues. Lawyers say there are three distinct parts the case, and dissect each, it is easier to understand where the judge comes and where ambiguities are.

First, the complainants, scientists studying adult stem cells, have the right to bring this matter? Second, is that their argument hESC research violates the Dickey Amendment, which prohibits federal funding for research that destroys embryos or night it reasonable? And thirdly, what is behind the preliminary funding stop order for Lamberth while it decides the case?

This is Science stab Insider to analyze each of these issues.

In the legal world, the first point is called "standing", that is, if the applicants have the right to bring a case to court. To have standing, the plaintiff "must have suffered actual damage caused by the action of the accused," said Suzanna Sherry expert from Vanderbilt University Law School in Nashville. Initially, Lamberth did not favorably position complainants, who at first were a larger group, including embryos, as an organization, Nightlight Christian Adoptions, which provides embryo-adoption services. He dismissed the case and the plaintiffs appealed. the Court of appeal agreed with DC partially Lamberth, but he found that two of the original scientific-plaintiffs James Sherley and Theresa Deisher-have been harmed by the funding of NIH research on hESCs. both remained on the suit while the rest has been removed.

This may seem exaggerated to scientists who claim, rightly, that the NIH fund much more research on adult stem cells as embryonic cells. But 'injury' from a legal point of view should not always be painful to count in courts. "The court has hesitated on the direct and immediate way of harm must be," said Sherry. Here, she believes, "evil is quite clear from their reserve fund is reduced." It may even be speculative-Sherry agrees that it's not as if the grant Sherley was denied because he went directly to an ES cell researcher. But, she adds, some courts consider "permanent should be interpreted very liberally because we want to pull people from the court "could have a case.

Standing requires not only that someone was hurt, but that with a favorable court decision, evil dissipate. And it is almost certain here, said Erwin Chemerinsky, dean of the University of California, Irvine, School of Law. "I am very surprised that they found standing in this case," he said. There is no indication that Sherley and Deisher (who never asked for NIH grant) funding would be allocated if the support hESC research has ended.

Harm also should be considered through the prism of wrongdoing. It's not like any scientist whose grant will unfunded can successfully pursue NIH. However, Sherry said, they claimed that the agency flipping a coin to make grants and to distribute funds to friends NIH officials, then they have a case.

Here, Sherley and Deisher allege that NIH violates an act of Congress in 1995 called the Dickey Amendment. Dickey-Wicker prohibits the Department of Health and human Services (HHS), which includes NIH to fund the destruction of human embryos or research funding which embryos are destroyed. When Dickey-Wicker was written 15 years ago, the hESC research has not yet begun. "All we talked about was directly on research on the embryo," for example, to improve the treatment of infertility or to better understand the biology of cancer, said R. Alta Charo, a law professor and bioethicist at the University of Wisconsin Law School who was a member of the NIH human embryo research Panel in the mid-190s, which examined how embryos can be used in research. "Dickey-Wicker was a reaction to that."

In 1999, Harriet Rabb, then Advocate General at HHS, found that Dickey-Wicker has not stopped government support for hESC research. The prohibition of funding, she wrote, "is not applicable to research using human pluripotent stem cells because these cells are not a human embryo in the legal definition." This argument was accepted by the Clinton, Bush and the Obama administration and Congress to appropriate money for hESC research. Rabb declined to comment for this story.

What Sherley and Deisher have a case that funding for hESC research violates Dickey -Wicker is tricky, say some scientists. for one, "we can say that there is a tension" which has just separated the destruction of the embryo for research on the resulting cells, says John Robertson, who is studying law and bioethics at the University of Texas School of law. Another problem is that in July 09 its guidelines on Human Research of stem cells, NIH statement of specific requirements regarding embryo donation for the newly derived lines, said Pilar Ossorio, a lawyer who studies ethics research at the University of Wisconsin Law School. The donation process is entirely separate from the search on the resulting cells. But NIH included this information in its guidelines to ensure that no undue influence on embryo donation for research, said Ossorio. An unintended consequence is that some may ask, "If NIH has not even finance the destruction of embryos, why these guidelines even talk about this?" She said.

advocates "The complainants stressed this in their brief on Friday. The Dickey-Wicker Amendment forbids the funding of research in which embryos are "knowingly subjected to risk of injury or death," they note. They then argue that "By creating a financial incentive for embryonic stem cell research an incentive that the confession even NIH will invest" hundreds of millions of dollars "-and specifying the precise means by which embryos are be destroyed in order to qualify for federal funding, the NIH necessarily and knowingly submits embryos at significant risk of injury or death. "

on the other hand, agreed with the plaintiffs" is to say that the [federal] agencies were wrong "all these years, Charo said. The courts tend to defer to federal agencies on the interpretation of laws as Dickey-Wicker, and the fact that the interpretation HHS has been consistent and has not been challenged in court until now may weaken because of complainants.

Ultimately, Robertson said, if you agree with Lamberth comes down to how you define "research". Lamberth, he said, is "a lumper, not a divider." In its preliminary injunction on August 23, Lamberth wrote that "if a step or 'piece of research' of an ESC research results in the destruction an embryo, the entire project is precluded from receiving federal funding by the Dickey-Wicker Amendment. "

This is" mushing things together in the real world of science are quite distinct "says Robertson. How hESCs are grown, that genetic or chemical signals cause them to differentiate into different cell types, how pluripotency is preserved- "each of them is almost a mini-world to among researchers." Important that this separation is key to assessing the case.

One of the most confusing elements of Sherley v. Sebelius is whether Bush rules, which allowed research on hESC lines that existed in 01, violates Dickey Wicker. In order yesterday, Lamberth wrote that they have not "The prior [Bush Administration] guidelines, of course, allowed research only on existing stem cell lines, excluding the additional destruction embryos. "

the current guidelines allow NIH research with newly derived lines, which Lamberth considered inseparable from the destruction of embryos." by his own logic, "says Charo, the ban Lamberth on financing "should apply to ... cell lines that are derived now." Cell lines derived 3 months or a year ago "have yet to be eligible for funding," she said.

A place where Lamberth is on shaky ground, lawyers believe, is in its decision to issue a preliminary injunction it 2 weeks ago. One case cited above by Lamberth called preliminary injunctions "an extraordinary remedy." They are granted only when it is considered very likely that the parties seek are likely to succeed in their case; when they suffer irreparable harm without one; and when an injunction will not "substantially" hurt others with an interest in the result and promote the public good.

Experts are particularly skeptical about the injury to Sherley and Deisher if funding for hESC research should continue while the judge considers the case.

The interest plaintiffs here "look very slight indeed, [and] do not seem dangerous enough ... to justify a preliminary injunction," said Robertson. This is especially true when considering the damage caused to the NIH and science programs that are now in chaos, he added.

Resolution may need to come from Congress, but we do not know exactly what that would entail. Undoing Dickey-Wicker entirely that could, legally speaking, the safest bet, but it may not be politically acceptable for legislators, particularly in an election year.

See our full coverage of this issue.